key: cord-0810134-fzhfjv4k
authors: Li, G.; Du, L.; Cao, X.; Wei, X.; Jiang, Y.; Lin, Y.; Nguyen, V.; Tan, W.; Wang, H.
title: Follow-up study on serum cholesterol profiles in recovered COVID-19 patients
date: 2020-12-11
journal: nan
DOI: 10.1101/2020.12.08.20245977
sha: 23c0aa26d99785a0bcbe493a57e5434d05f56ad9
doc_id: 810134
cord_uid: fzhfjv4k

COVID-19 patients develop hypolipidemia. However, it is unknown whether lipid levels have improved in recovered patients. In this study, a 3-6 month follow-up study was performed to examine serum levels of laboratory values in 107 discharged COVID-19 patients (mild = 59; severe/critical = 48; diagnoses on admission). 61 patients had a revisit chest CT scan. A Wilcoxon signed-rank test was used to analyze changes in laboratory values. LDL-c and HDL-c levels were significantly higher at follow-up than at admission in severe/critical cases (p < 0.05). LDL-c levels were significantly higher at follow-up than at admission in mild cases (p < 0.05). With adjustment of the factor of traditional Chinese medicine, LDL-c and HDL-c levels were significantly improved at follow-up than at admission in severe/critical cases (p < 0.05). Increases in HDL-c significantly correlated with increases in numbers of white blood cells (p<0.001) and decreases in levels of C-reactive protein (p < 0.05) during patients' recovery. Residue lesions were observed in CT images in 69% (42 of 61) of follow-up patients. We concluded that improvements of LDL-c, HDL-c and incomplete absorption of lung lesions were observed at follow-up for recovered patients, indicating that a long-term recovery process could be required.

Coronavirus disease 2019 , which has become a major threat to the global public 53 health system [1] , is caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) 54

[2]. As of October 3, 2020, more than 34.7 million COVID-19 infections and 1 million deaths have 55 been reported in 188 countries and regions. China reported 90 thousands cases and 4,739 deaths 56 which were mainly from the original epicenter, Wuhan [3] . Scientists are just beginning to 57 understand the nature of the harm caused by this disease. The SARS-Cov-2 spike protein 58 mediates the entrance of the virus into host cells via surface angiotensin-converting enzyme 2 59 (ACE2) [4, 5] . Host protease transmembrane, serine protease 2 (TMPRSS2) promotes SARS-60

CoV-2 entry into target cells, which are thought to be host determinants for viral infection in the 61 initial stage [6] . COVID-19 patients may be asymptomatic or symptomatic. The time from 62 exposure to onset of symptoms is about 5.1 days [7] . Pathologically, almost every vital organ in 63 the body, including the lungs, heart, liver, kidneys, eyes, blood vessels, intestines, and brain, can 64 be injured by SARS-CoV-2, leading to devastating consequences [8] . Acute and diffuse lung 65 injuries cause increases in a series of serum cancer biomarkers in patients [9] . Damage to the 66 lungs can be long-term for some recovered patients; this has also been observed in surviving 67 severe acute respiratory syndrome (SARS) patients [10] . 68

Patients with metabolic-associated preconditions are susceptible to SARS-CoV-2 attack and are 69 likely to experience more pronounced symptoms [11] . One pathogenic cofactor associated with 70 hypertension, obesity, diabetes mellitus, and cardiovascular disorders is hypercholesterolemia. 71

We and others have recently reported hypolipidemia in hospitalized COVID-19 patients [12] [13] [14] [15] . 72

An association between decreases in lipid levels and the severity of the symptoms in patients has 73 been revealed [12] [13] [14] . Furthermore, emerging evidence has shown that SARS-CoV-2 has a 74 direct impact on the downregulation of lipid-metabolism-related proteins and pathways, leading 75 to dyslipidemia [11, 16] . In addition, dyslipidemia associated with SARS-CoV-1 has also been 76 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 reported [17] . Altered lipid metabolism has been shown in recovered SARS-CoV-1 patients 12 77 years after infection [18] . These reports demonstrate that dyslipidemia is an important clinical 78 manifestation in patients with coronavirus-related diseases, perhaps reflecting one aspect of the 79 complicated evolving pathological progressions seen in patients. In this study, we performed a 80 follow-up investigation of lipid profiles and other laboratory values in COVID-19 patients from our 81 previously reported cohort [19] . We found that there were significant improvements of coagulation 82 and liver laboratory values , including D-dimer, antithrombin III (ATIII), fibrin degradation product 83 (FDP), fibrinogen (FIB), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and 84 gamma-glutamyl transferase (GGT) in patients at follow-up compared to time of admission. 85

However, partial recovery of low-density lipoprotein cholesterol (LDL-c) levels and incomplete 86 absorption of lung lesions were observed at follow-up, indicating that a long-term recovery 87 process and the development of sequelae such as pulmonary fibrosis could be expected in some 88 patients. 89

A total of 107 COVID-19 cases were included in this follow-up study: 59 mild and 48 severe/critical 92 cases (based on patient diagnosis at time of admission). A CONSORT flow diagram is shown in 93 Figure. 1. The age for all patients was 65 (60, 70) (median (IQR)) years. The ages for patients in 94 the two subgroups were as follows: 65 (51, 69) for mild and 66 (62, 74) for severe/critical cases 95 (Table 1 ). The overall follow-up time was 100 (96, 116) days after discharge. The ratios for 96 comorbidities, days until follow-up, and gender disparity among patients in each category are 97 listed in Table 1 . An insignificant percentage of patients in the subgroups (about 15%-18%) used 98 cholesterol-lowering drugs (Table 1) . 99 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 

Our previous studies have shown that serum cholesterol levels at the time of admission were 117 significantly lower in COVID-19 patients than in normal subjects [12, 13] . In this follow-up study, 118 we compared patient lipid levels at 3-6 months after discharge to those at the time of admission. 119

Both LDL-c, HDL-c and TC were significantly higher at follow-up than at the time of admission in 120 severe / critical cases (Table 2) . LDL-c and TC levels were significantly higher at follow-up than 121 at the time of admission in mild patients (Table 2) . Surprisingly, 11% of patients (12 of 107) 122

showed a 15% or more decrease in LDL-c levels at follow-up as compared to the time of 123 admission; these patients included 4 mild and 8 severe/critical cases. In addition, 13% of patients 124 (14 of 107) showed a 15% or more decrease in HDL-c levels at follow-up as compared to the time 125 of admission; these patients included 5 mild and 9 severe/critical cases. There were two cases in 126 

9 (15%) 7 (18%) n.s.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint which both LDL-c and HDL-c levels were 15% or more reduced at follow-up as compared to the 127 time of admission. 128 Data are presented as mean (SD) in reference ranges or median (IQR) unless stated otherwise. 132

A Wilcoxon signed-rank test (two-sided) is used to compare variables at the time of admission 133 and at follow-up from the same subjects within groups (mild and severe/critical cases). subgroup took cholesterol-lowering drugs than those in non-TCHM subgroup (table 3) . 152 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint presented as median (IQR) or n (%). The p value is calculated using a Wilcoxon signed-rank test 159

(two-sided) to compare variables at the times of admission with follow-up from the same subjects 160 within subgroups. In both mild and severe groups, the lipid values at the time of admission or 161 follow-up in the non-TCHM subgroup is compared with that in the TCHM subgroup using a Mann-162 Whitney U test; the p values are not shown since no statistical significance is found. *Fisher 163 extract test is used. 164 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint (Table 2) . 186

We performed a Pearson correlation analysis to calculate the correlation coefficiency between mild or moderate liver injury [13] . In this study, patient ALT, ALP, and GGT levels were significantly 224 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [15]. All of these hypotheses will lead to more and novel insights into the nature of this disease. 234

The dynamics of lipid levels in a small cohort of our longitudinal study and in two cases in other 235

reports have shown that cholesterol levels were low at the time the patients were hospitalized, 236 remained low during disease progression, and returned to baseline levels in patients who were 237 discharged [12, 14, 15] . To our surprise, a small portion of patients (12% to 14%) showed a 238 decrease in LDL-c or HDL-c levels of 15% or more at follow-up as compared to the time of 239 admission. The low lipid levels in these patients were probably due to medications or nutritional 240 supplements taken during their own recovery process at home, for example, profound and acute 241 dietary changes. It would be interesting to find out whether those patients with lower LDL-c or 242 HDL-c levels at follow-up were from socioeconomically underrepresented populations. Although 243 it is less likely, there could be a long-term sequela of lipid abnormality caused by or associated 244 with viral infection in COVID-19 patients; there is no evidence to support the notion that SARS-245

Emerging evidence has supported coagulation as an independent mortality factor in COVID-19 247 patients. Coagulopathies have been found in the early stages of the disease [22] [23] [24] and in 248 nonsurviving patients [25] . Patients have shown elevated coagulation and cardiac biomarkers 249 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 such as D-dimer, fibrinogen, high-sensitivity troponin I and creatinine kinase-myocardial band [26, 250 27 ]. In our follow-up study, coagulation laboratory values, including D-dimer, ATIII, FDP, and FIB, 251 were significantly lower in patients at follow-up as compared to the time of admission across all 252 subgroups, indicating improvements from coagulopathies. However, we did not find significant 253 correlations between the restoration of LDL-c or HDL-c levels and decreases in levels of these 254 coagulation values; this suggests that recovery from dyslipidemia and improvements from 255 coagulopathies are probably involving different pathways at different paces. 256

Incomplete resolution of lung lesions was observed in 69% patients in the follow-up CT 257 examinations, suggesting pulmonary fibrosis as a potential long-term sequela for many COVID- These data suggest that aberrant wound healing in COVID-19 survivors, which is evidenced by 264 GGO and residue lesion patterns, may lead to pulmonary fibrosis; larger studies are needed to 265 verify this notion. 266

There were several limitations of this study. First, less than one-fifth of the patients from our 267 original cohort participated in this study, which might cause a biased representative sample group 268 from the original cohort. Second, the sample size for follow-up critical cases was limited; this might 269 lead to an overall insignificant increase in levels of LDL-c in this subgroup. Third, many patients 270 might have been taking various medications or remedies at home for recovery, including Chinese 271 traditional medicines or nutritional supplements. In this study, we found that about 58% of patients 272 in mild group and 37% of patients in severe group had taken TCHMs during their illness or / and 273 recovery courses. Our data indicated that TCHMs might have a negative impact on the 274 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint improvement of lipid profiles in patients with severe symptoms. However, due to the complexity 275 of ingredients in those TCHMs, it will be very difficult to determine which factor(s) and how they 276 interfere with lipid metabolisms in some patients' recoveries in the severe group; this will need a 277 thorough investigation in future. We, however, did not find so far that TCHMs caused any 278 significant changes in the overall lipid profiles at the time of admission and follow-up crossing all 279 the subgroups. Therefore, TCHMs might have a minor effect on lipid values in our patient which 280 resulted in a negligible impact on the conclusions we drew in this study. We are aware that these 281 data and analyses only apply to this specific Chinese population. Fourth, the lipid profiles of 282 patients prior to discharge were crucial to determine the contributive factors to the decreased 283 LDL-c or HDL-c levels in a small portion of patients at follow-up as compared to admission, which 284 were lacking. Fifth, a continuous long-term follow-up is needed in order to monitor the dynamics 285 of lipid profiles and CT abnormalities during the recovery process for a large cohort of COVID-19 286 patients in order to better predict potential sequelae, such as lung fibrosis; this will be our future 287 research goal. Lastly, the characteristics of lipoproteins in our cohort was unknown. We also did 288 not know the cellular cholesterol levels in COVID-19 in this study; such information could provide 289 us insights into the molecular mechanisms underlying dyslipidemia in COVID-19. Whether and 290 how cholesterol or lipoproteins participate regulation of SARS-CoV-2 entry of host cells and viral 291

production are yet to be determined, which will our primary goal in future investigations. 292

Collectively, our data show improvements of LDL-c and HDL-c and incomplete absorption of 293 lung lesions in COVID-19 patients at a 3-6-month follow-up, indicating a long-term recovery 294 process and the development of potential sequelae such as pulmonary fibrosis. 295

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 This follow-up study was carried out at the Cancer Center at the Union Hospital of Tongji Medical 298

College in Wuhan, P. R. China, and was approved by the Institutional Review Board (IRB) at the 299 Union Hospital. The requirement for written informed consent was waived by the IRB committee. 300

Our previous study included a cohort of 597 COVID-19 patients admitted to the hospital between 301 admission with those at follow-up, the patients were grouped into the same categories assigned 307

to them in the original study, which were based on their diagnoses on admission,[13] that is, mild 308 (n = 59) and severe/critical (n = 48) cases. Briefly, clinical diagnostic criteria and guideline were 309 as the follows: (1) mild group, patients with onset of symptoms including fever, cough, fatigue, 310 headache, diarrhea, and so forth, with or without mild pneumonia; (2) severe group, patients 311 showed dyspnea, acute respiratory stress, decrease in blood oxygen saturation, lung infiltrates, 312 multiple peripheral ground-glass opacities on both lungs; and (3) critical group, patients presented 313 respiratory or multiple organ failure and septic shock [13] . A revisit CT scan was performed on a 314 total of 61 patients as their standard cares of follow-up examination which was covered by their 315 health insurance providers. A CONSORT flow diagram is shown in Fig. 1 . 316

Many patients were prescribed traditional Chinese herbal medications (TCHM) by their local 317 healthcare workers as a standard supplementary treatment of COVID-19 in Wuhan. Two typical 318

TCHMs were widely given to patients with mild symptoms or at the onset of symptoms or/and 319 after discharge from hospitals for one or two weeks according to Chinese Center for Disease 320

Control (CDC) guidelines. The herbal ingredients for the first TCHM were as follows: bupleurum 321 chinense, astragalus, coix lacryma-jobi, atractylodes lancea, ophiopogon japonicus, glehnia 322 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint littoralis, licorice, honeysuckle, bombyx batryticatus, periostracum cicada, rhubarb, and Curcuma 323 longa. The herbal ingredients for the second TCHM were as follows: astragalus, atractylodes 324 macrocephala, divaricate saposhniovia root, cyrtomium fortunei, honeysuckle, eupatorium fortune, 325

and Chenpi. In order to adjust the factor of THCM for a further analysis, we categorized patients 326 into non-TCHM or TCHM subgroup to assess the potential effect of these THCMs on patients' 327 lipid profiles. Nos. OSR6283, OSR6587, and OSR6616). D-dimer, ATIII, FDP, and FIB were tested on a Stago 337 STAR analyzer using the manufacturer's reagents (Stago, Parsippany, New Jersey, USA). C-338 reactive protein (CRP) was determined using a BC-5390 analyzer (Mindray, Shenzhen, 339 Guangzhou, P. R. China). The clinical laboratory data included in this study were from blood 340 samples drawn fasting on the morning of the day of follow-up, a standard time and procedure of 341 blood drawn for laboratory tests in our hospital including blood sample collections at admission in 342 our previous study. [13] Electronic data from the time of the patients' hospitalization, including 343 demographic information, clinical symptoms and diagnosis, laboratory tests, and treatment data, 344

were also extracted for comparison. 345

CT scanners (GE LightSpeed 16, GE VCT LightSpeed 64 from GE Healthcare, Chicago, Illinois, 346 USA) were used to take chest CT scans with the following parameters: tube voltage = 120 kVp; 347 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint current intelligent control = 30-300 mA; and slice thickness/interval = 0.6-1.5 mm. The following 348 typical abnormal patterns for viral pneumonia were reported in COVID-19 CT images: [32] ground 349 glass opacities (GGO), consolidation/nodules, and shadows. 350 351

Statistical analyses were performed with the statistical software SPSS (IBM, Armonk, New York, 353 USA). Data are presented as mean (SD) or median (interquartile range, IQR). A Wilcoxon signed-354 rank test (two-sided) was used to compare patient laboratory values at admission and follow-up. 355

Mann-Whitney U test was used to compare differences between two groups. A Pearson 356 correlation analysis was used to calculate correlation coefficiency. P values of p < 0.05 were 357 considered as statistically significant. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.08.20245977 doi: medRxiv preprint

Characteristics of and important lessons from the coronavirus disease 372 2019 (covid-19) outbreak in china: Summary of a report of 72314 cases from the chinese center 373 for disease control and prevention

Evolution of the novel coronavirus 375 from the ongoing wuhan outbreak and modeling of its spike protein for risk of human 376 transmission

Covid-19 dashboard by the center for systems science and engineering (csse) at johns hopkins 378 university (jhu)

Genomic 380 characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and 381 receptor binding

Receptor recognition by novel coronavirus from 383 wuhan: An analysis based on decade-long structural studies of sars

Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway 387 epithelial cells and is detected in specific cell subsets across tissues

The 390 incubation period of coronavirus disease 2019 (covid-19) from publicly reported confirmed 391 cases: Estimation and application

Serum lipid metabolic derangement is 393 associated with disease progression during chronic hbv infection

Elevations of serum cancer biomarkers 396 correlate with severity of covid-19

Long-term bone and 398 lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-399 year follow-up from a prospective cohort study

Presenting characteristics, comorbidities, and outcomes 402 among 5700 patients hospitalized with covid-19 in the new york city area

Low-density lipoprotein is a potential 405 predictor of poor prognosis in patients with coronavirus disease 2019

Hypolipidemia is associated with the 408 severity of covid-19

Declined serum high density lipoprotein cholesterol is 410 associated with the severity of covid-19 infection

Covid-19-associated 413 dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic 414 approaches

Coronavirus covid-19 (sars-cov-2), johns hopkins abx guide

Altered lipid metabolism in 421 recovered sars patients twelve years after infection

Srisurapanon 424 S. Ctla-4 and its ligands on the surface of t-and b-lymphocyte subsets in chronic hepatitis b virus 425 infection

The role of high cholesterol in age-related covid19 427 lethality

Cholesterol: A new game player accelerating 429 vasculopathy caused by sars-cov-2?

Venous and arterial thromboembolic complications in covid-19 patients 433 admitted to an academic hospital in milan, italy

Incidence of thrombotic complications in critically ill 437 icu patients with covid-19

High risk of thrombosis in patients with severe sars-cov-2 440 infection: A multicenter prospective cohort study

Abnormal coagulation parameters are associated with poor 443 prognosis in patients with novel coronavirus pneumonia

Association of 446 cardiac injury with mortality in hospitalized patients with covid-19 in wuhan

Diagnostic utility of clinical 449 laboratory data determinations for patients with the severe covid-19

Follow-up study on pulmonary function and 452 lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after 453 discharge

The 1-year impact of severe acute 455 respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of 456 survivors

Follow-458 up chest radiographic findings in patients with mers-cov after recovery

Anormal 461 pulmonary function and residual ct abnormalities in rehabilitating covid-19 patients after 462 discharge